NCT07168980RecruitingPhase 2/3
Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
Intensive Chemotherapy Combined With Early, Adequate, and Intensive Use of Rituximab for Aggressive B-NHL in Children and Adolescents
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 87 (estimated)
- First submitted
- 4 Sept 2025
- Start date
- Jul 2025
- Primary completion date
- Jun 2030
- Lead sponsor
- Children's Cancer Group, China
- Diseases
- Childhood cancers
- NCT number
- NCT07168980
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 87
- From Jul 2025 to the primary completion date, Jun 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior exposure to rituximab
Other illness
- Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.
- Evidence of pregnancy or lactation period. Past or current anti-cancer treatment except corticosteroids during less than one week.
- Hepatitis B carrier status history of HBV or positive serology.
Other
- Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study
- Tumor cell negative for CD20
Who the study is looking for
- Histology or cytologically confirmed mature B-cell NHL/AL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)
- Able to comply with scheduled follow-up and with management of toxicity
- Signed informed consent
Age in the registry: - to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Children's Medical Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.